Free Newsletter
From Iceland's woes, an $8B Actavis deal?
If Iceland's financial crisis was an earthquake, then this is a major aftershock: Actavis Group, one of the world's biggest generics makers, may go on the block for as much as $8 billion. Actavis is 80 percent-owned by Icelandic billionaire Thor Bjorgolfsson's private equity firm Novator. And Bjorgolfsson saw a big portion of his wealth go down the drain when Landsbanki Islands collapsed earlier this month.
Actavis had already hired Merrill Lynch to sift through its various options: sale, takeover, merger or public stock listing. Sources are now telling the Wall Street Journal that Bjorgolfsson's bank-related pain may push him to do a deal. A Novator spokesman said Actavis shareholders aren't looking to do a hasty deal, however. Any sale or merger wouldn't happen before next year, he said.
The global financial crisis could impede potential buyers, however. With companies strapped for credit, the M&A market has slowed considerably.
- read the WSJ article
Related Articles:
Crunch paves way for pharma deals
Pharma is cash rich abroad, but debt will rise
DeCode restructures, sells non-core assets
DeCode feels the sting of financial crisis
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





